ANI PHARMACEUTICALS, INC Other Interest and Dividend Income
ANI PHARMACEUTICALS, INC (ANIP) reported Other Interest and Dividend Income of $1.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherInterestAndDividendIncome · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC other interest and dividend income for the quarter ending 2026-06-30 was $1.01M, a 18.59% decline year-over-year.
- ANI PHARMACEUTICALS, INC other interest and dividend income for the quarter ending 2026-03-31 was $1.00M, a 18.82% decline year-over-year.
- ANI PHARMACEUTICALS, INC other interest and dividend income for the quarter ending 2025-12-31 was $1.14M, a 17.55% decline year-over-year.
- ANI PHARMACEUTICALS, INC other interest and dividend income for the quarter ending 2025-09-30 was $1.26M, a 23.91% decline year-over-year.
- ANI PHARMACEUTICALS, INC other interest and dividend income for fiscal 2025 was $4.87M, a 22.22% decline from fiscal 2024.
- ANI PHARMACEUTICALS, INC other interest and dividend income for fiscal 2024 was $6.27M, a 143.06% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC other interest and dividend income for fiscal 2023 was $2.58M.
- ANI PHARMACEUTICALS, INC other interest and dividend income for fiscal 2022 was $0.00.
| Period end | Other Interest and Dividend Income 3 month | Other Interest and Dividend Income 6 month | Other Interest and Dividend Income 9 month | Other Interest and Dividend Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.01M 10-Q · filed 2026-08-07 | $2.01M 10-Q · filed 2026-08-07 | $3.15M derived: sum of 3 quarters · filed 2026-08-07 | $4.41M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-08 | $2.15M derived: sum of 2 quarters · filed 2026-05-08 | $3.40M derived: sum of 3 quarters · filed 2026-05-08 | $4.64M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.40M derived: sum of 2 quarters · filed 2026-02-27 | $3.64M derived: sum of 3 quarters · filed 2026-08-07 | $4.87M 10-K · filed 2026-02-27 |
| 2025-09-30 | $1.26M 10-Q · filed 2025-11-07 | $2.49M derived: sum of 2 quarters · filed 2026-08-07 | $3.73M 10-Q · filed 2025-11-07 | $5.12M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.24M 10-Q · filed 2026-08-07 | $2.48M 10-Q · filed 2026-08-07 | $3.86M derived: sum of 3 quarters · filed 2026-08-07 | $5.51M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.24M 10-Q · filed 2026-05-08 | $2.62M derived: sum of 2 quarters · filed 2026-05-08 | $4.28M derived: sum of 3 quarters · filed 2026-05-08 | $5.91M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.04M derived: sum of 2 quarters · filed 2026-02-27 | $4.67M derived: sum of 3 quarters · filed 2026-02-27 | $6.27M 10-K · filed 2026-02-27 |
| 2024-09-30 | $1.65M 10-Q · filed 2025-11-07 | $3.28M derived: sum of 2 quarters · filed 2025-11-07 | $4.88M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $1.63M 10-Q · filed 2025-08-08 | $3.23M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $1.60M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $2.58M 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |